000859645 001__ 859645
000859645 005__ 20240625095128.0
000859645 0247_ $$2doi$$a10.3390/antib7030026
000859645 0247_ $$2Handle$$a2128/21828
000859645 0247_ $$2WOS$$aWOS:000448330700006
000859645 037__ $$aFZJ-2019-00493
000859645 082__ $$a540
000859645 1001_ $$0P:(DE-Juel1)174546$$aCapelli, Riccardo$$b0$$ufzj
000859645 245__ $$aBPSL1626: Reverse and Structural Vaccinology Reveal a Novel Candidate for Vaccine Design Against Burkholderia pseudomallei
000859645 260__ $$aBasel$$bMDPI$$c2018
000859645 3367_ $$2DRIVER$$aarticle
000859645 3367_ $$2DataCite$$aOutput Types/Journal article
000859645 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1552413352_13869
000859645 3367_ $$2BibTeX$$aARTICLE
000859645 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000859645 3367_ $$00$$2EndNote$$aJournal Article
000859645 520__ $$aDue to significant advances in computational biology, protein prediction, together with antigen and epitope design, have rapidly moved from conventional methods, based on experimental approaches, to in silico-based bioinformatics methods. In this context, we report a reverse vaccinology study that identified a panel of 104 candidate antigens from the Gram-negative bacterial pathogen Burkholderia pseudomallei, which is responsible for the disease melioidosis. B. pseudomallei can cause fatal sepsis in endemic populations in the tropical regions of the world and treatment with antibiotics is mostly ineffective. With the aim of identifying potential vaccine candidates, we report the experimental validation of predicted antigen and type I fimbrial subunit, BPSL1626, which we show is able to recognize and bind human antibodies from the sera of Burkholderia infected patients and to stimulate T-lymphocytes in vitro. The prerequisite for a melioidosis vaccine, in fact, is that both antibody- and cell-mediated immune responses must be triggered. In order to reveal potential antigenic regions of the protein that may aid immunogen re-design, we also report the crystal structure of BPSL1626 at 1.9 Å resolution on which structure-based epitope predictions were based. Overall, our data suggest that BPSL1626 and three epitope regions here-identified can represent viable candidates as potential antigenic molecules.
000859645 536__ $$0G:(DE-HGF)POF3-899$$a899 - ohne Topic (POF3-899)$$cPOF3-899$$fPOF III$$x0
000859645 588__ $$aDataset connected to CrossRef
000859645 7001_ $$0P:(DE-HGF)0$$aPeri, Claudio$$b1
000859645 7001_ $$0P:(DE-HGF)0$$aVilla, Riccardo$$b2
000859645 7001_ $$0P:(DE-HGF)0$$aNithichanon, Arnone$$b3
000859645 7001_ $$0P:(DE-HGF)0$$aConchillo-Solé, Oscar$$b4
000859645 7001_ $$0P:(DE-HGF)0$$aYero, Daniel$$b5
000859645 7001_ $$0P:(DE-HGF)0$$aGagni, Paola$$b6
000859645 7001_ $$0P:(DE-HGF)0$$aChiari, Marcella$$b7
000859645 7001_ $$0P:(DE-HGF)0$$aLertmemongkolchai, Ganjana$$b8
000859645 7001_ $$0P:(DE-HGF)0$$aCretich, Marina$$b9
000859645 7001_ $$0P:(DE-HGF)0$$aDaura, Xavier$$b10
000859645 7001_ $$00000-0002-9253-5170$$aBolognesi, Martino$$b11
000859645 7001_ $$0P:(DE-HGF)0$$aColombo, Giorgio$$b12$$eCorresponding author
000859645 7001_ $$0P:(DE-HGF)0$$aGourlay, Louise J.$$b13$$eCorresponding author
000859645 773__ $$0PERI:(DE-600)2661514-9$$a10.3390/antib7030026$$gVol. 7, no. 3, p. 26 -$$n3$$p26 -$$tAntibodies$$v7$$x2073-4468$$y2018
000859645 8564_ $$uhttps://juser.fz-juelich.de/record/859645/files/antibodies.pdf$$yOpenAccess
000859645 8564_ $$uhttps://juser.fz-juelich.de/record/859645/files/antibodies.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000859645 909CO $$ooai:juser.fz-juelich.de:859645$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000859645 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)174546$$aForschungszentrum Jülich$$b0$$kFZJ
000859645 9131_ $$0G:(DE-HGF)POF3-899$$1G:(DE-HGF)POF3-890$$2G:(DE-HGF)POF3-800$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000859645 9141_ $$y2019
000859645 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000859645 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000859645 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000859645 915__ $$0StatID:(DE-HGF)0112$$2StatID$$aWoS$$bEmerging Sources Citation Index
000859645 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000859645 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000859645 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000859645 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000859645 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000859645 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000859645 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000859645 920__ $$lno
000859645 9201_ $$0I:(DE-Juel1)IAS-5-20120330$$kIAS-5$$lComputational Biomedicine$$x0
000859645 9801_ $$aFullTexts
000859645 980__ $$ajournal
000859645 980__ $$aVDB
000859645 980__ $$aUNRESTRICTED
000859645 980__ $$aI:(DE-Juel1)IAS-5-20120330
000859645 981__ $$aI:(DE-Juel1)INM-9-20140121